All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital
Ping An Biomedical Enters Investment Memorandum With Future Biotechnology For Up To $90M
Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry
Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation
Ping An Bio Announces Non-Binding $30M Cash Investment, $60M Acquisition Plan With Future Biotechnology
Ping An Biomedical Enters Share Purchase Agreements With Several Investors, 58 Group's Yao Jinbo, Amiba Capital's Wang Donghui, And Magcloud's Li Daxue
Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter
Ping An Biomedical Receives Nasdaq Deficiency Letter For Failing To Meet $1 Minimum Bid Price, Granted Compliance Period Until May 25, 2026
Majestic Ideal Holdings Ltd Announces Approval of Name Change to "Ping An Biomedical Co., Ltd." at Extraordinary General Meeting
Majestic Ideal Holdings Limited Announced Closing of Initial Public Offering
Majestic Ideal Holdings Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
